Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Last updated: June 25, 2025
Sponsor: Vir Biotechnology, Inc.
Overall Status: Active - Recruiting

Phase

1

Condition

Neoplasms

Treatment

Pembrolizumab

VIR-5525

Clinical Study ID

NCT06960395
VIR-5525-V101
U1111-1294-8156
2023-508555-39
AMX-525
  • Ages > 18
  • All Genders

Study Summary

This Phase 1, first-in-human (FIH), dose-escalation and dose-expansion study is designed to evaluate the safety, PK, and preliminary anti-tumor activity of VIR-5525 as a monotherapy and in combination with pembrolizumab in participants with solid tumors that are known to express EGFR.

The study will be conducted in the following 4 parts:

  • Part 1: VIR-5525 monotherapy dose escalation

  • Part 2: VIR-5525 monotherapy dose expansion

  • Part 3: VIR-5525 plus pembrolizumab dose escalation

  • Part 4: VIR-5525 plus pembrolizumab dose expansion

Eligibility Criteria

Inclusion

Inclusion Criteria:

I 01. Are ≥ 18 years of age, or at the country's legal age of majority of the legal adult age is >18 years, at the time of signing the ICF.

I 02. Have an ECOG performance status of 0 to 1.

I 03. Have a life expectancy of at least 12 weeks.

I 04. Have histological, pathological, or cytological confirmation of disease type that is unresectable, locally advanced, or metastatic.

I 05. Have measurable disease per RECIST v1.1 as assessed by the local site investigator/radiology. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.

I 06. Have diseases under study, lines of therapy, and biomarker status, as follows:

Have one of the following:

• (Parts 1 and 3): NSCLC (nonsquamous or squamous histology), CRC, HNSCC, or CSCC.

Note: Participants with nasopharyngeal tumors are eligible. Note: Participants with upper esophageal or salivary gland tumors are not eligible.

OR

• Have a solid tumor with EGFR amplification (as previously determined locally with an analytically validated assay in a certified testing laboratory).

Have no available standard systemic therapy; or standard therapy is intolerable, not effective, or not accessible; or participant has refused standard therapy.

Exclusion

Exclusion Criteria:

E 01. Are a WOCBP with a positive serum or urine pregnancy test within 72 hours prior to treatment.

E 02. Have acute or chronic infections, including the following:

  • Acute or chronic active Epstein-Barr virus (EBV) infection (Exception: asymptomaticEBV-positive participants are still eligible)

  • Chronic active EBV disease defined as a chronic illness lasting at least 6 months,an increased EBV level in either the tissue or the blood, and lack of evidence of aknown underlying immunodeficiency

  • History of hepatitis B infection (defined as hepatitis B surface antigen [HBsAg]reactive) or known active hepatitis C virus (HCV) infection (defined as HCV [HCVRNA; qualitative] is detected)

  • History of HIV infection. No HIV testing is required unless mandated by the localhealth authority.

  • Active infection requiring systemic therapy within 14 days of Cycle 1 Day 1

  • Known positive COVID-19 test result at screening (Exception: If follow-up test isnegative, participants may be eligible if asymptomatic and upon consultation withmedical monitor)

E 03. Have a concomitant medical or inflammatory condition that may increase the risk of toxicity to VIR-5525 or pembrolizumab, per the investigator

E 04. Have a QT interval corrected by Fridericia's method (QTcF) that is >480 ms

E 05. Have received prior systemic anti-cancer therapy, including investigational agents, within 5 half-lives prior to first dose of study intervention. For drugs with a long t1/2, such as mAbs, or for drugs for which the t1/2 is not known, the last dose should not have been within 28 days prior to first dose of study intervention.

Note: If the participant has had major surgery, the participant must have recovered adequately from the procedure and/or any complications from the surgery prior to starting study intervention.

E 06. Have received prior radiotherapy within 2 weeks of start of study intervention Note: Participants must have recovered from all radiation-related toxicities to Grade ≤1 or baseline, must not require corticosteroids, and must not have had radiation pneumonitis.

Exception: External beam radiotherapy, including palliative external radiation, is allowed.

A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.

The above information is not intended to contain all considerations relevant to the potential participation in a clinical trial.

Study Design

Total Participants: 450
Treatment Group(s): 2
Primary Treatment: Pembrolizumab
Phase: 1
Study Start date:
July 01, 2025
Estimated Completion Date:
August 31, 2029

Connect with a study center

  • Wollongong Hospital

    Wollongong, New South Wales 2500
    Australia

    Active - Recruiting

  • Princess Alexandra Hospital

    Woolloongabba, Queensland 4102
    Australia

    Site Not Available

  • Honor Health Research Institute

    Scottsdale, Arizona 85258-4566
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.